

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 30 of June 2026

	30.06.2026	31.12.2025
	EUR'000	EUR'000
ASSETS		
Non-current assets		
Property, plant and equipment	17 249	17 889
Intangible assets	1 953	1 844
Investments in subsidiaries	34	34
Trade receivables	2 603	2 603
Total non-current assets	21 839	22 370
Current assets		
Inventories	9 145	9 165
Trade and other receivables	41 951	40 466
Cash and cash equivalents	56	577
Total current assets	51 152	50 208
Total assets	72 991	72 578
LIABILITIES		
Equity		
Share capital	49 033	49 033
Reserves	7 525	7 525
Retained earnings	5 470	3 075
Total	62 028	59 634
Non-current liabilities		
Long-term loans	573	789
Deferred tax liabilities	637	637
Retirement benefit obligations	182	182
Total non-current liabilities	1 392	1 608
Current liabilities		
Trade and other liabilities	5 072	5 590
Short-term loans	4 003	4 752
Current portion of long-term loans	440	476
Current corporate income tax	-	29
Other tax liabilities	56	489
Total current liabilities	9 571	11 337
Total liabilities	10 963	12 944
Total equity and liabilities	72 991	72 578

Date of preparation: 23.07.2026
Sofia

Prepared by:.....
/Tsvetelina Pandeva/


Executive Director:.....
/Biser Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 30 of June 2026

	30.06.2026	30.06.2025
	EUR'000	EUR'000
Revenue	19 141	16 365
Other income	1	25
Total income	19 142	16 390
Carrying amount of goods sold	(970)	(939)
Changes in inventories of finished products and work in progress	684	(24)
Materials and services	(12 261)	(9 122)
Personnel expenses	(2 895)	(2 688)
Depreciation / amortisation expenses	(758)	(708)
Other expenses	(237)	(176)
Finance income	6	30
Finance costs	(136)	(148)
Total expenses	(16 567)	(13 775)
Profit before taxation	2 575	2 615
Corporate income tax expense	(180)	(169)
Profit/Loss for the period	2 395	2 446
Total comprehensive income for the period	2 395	2 446
Earnings per share / in EUR per 1 share /	0.03	0.03

Date of preparation: 23.07.2026
Sofia


Prepared by:.....
/ Tsvetelina Pandeva /


Executive Director:.....
/Biser Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 30 of June 2026


	30.06.2026	30.06.2025
	<i>EUR'000</i>	<i>EUR'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	12 535	11 246
Payments to suppliers of materials, goods and services	(6 130)	(5 718)
Payments to personnel	(2 881)	(2 701)
Foreign currency exchange gains/losses	(8)	(9)
Payments of interest and dividends	(209)	(103)
Other proceeds / payments	(2 659)	(2 131)
Net cash flows	648	584
Cash flows from investing activities		
Payments on non-current assets acquired	(110)	(325)
Net cash flows	(110)	(325)
Cash flows from financial activities		
Proceeds from loans	81	114
Payments on loans	(830)	(113)
Payment of interest, dividends	(87)	(114)
Payments on finance lease	(223)	(133)
Net cash flows	(1 059)	(246)
Change in cash and cash equivalents	(521)	13
Cash and cash equivalents at the beginning of the period	577	40
Cash and cash equivalents at the end of the period	56	53

Date of preparation: 23.07.2026

Sofia



Prepared by:.....
 / Tsvetelina Pandeva /




Executive
 Director:.....
 /Biser Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 30 of June 2026

	Registered (share) capital <i>EUR'000</i>	Revaluation reserves <i>EUR'000</i>	Other reserves <i>EUR'000</i>	Retained earnings / loss <i>EUR'000</i>	Total equity <i>EUR'000</i>
Balance as of 01.01.2025	46 937	2 208	4 488	2 327	55 960
Profit/loss for the period				3 075	3 075
Other comprehensive income		598			598
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		598		3 075	3 673
Issue of shares by the owners	2 096		231	(2 327)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period	2 096		231	(2 327)	
Balance as of 31.12.2025	49 033	2 806	4 719	3 075	59 633
Balance as of 01.01.2026	49 033	2 806	4 719	3 075	59 633
Profit/loss for the period				2 395	2 395
Other comprehensive income					
Total comprehensive income				2 395	2 395
Issue of shares by the owners					
Total amount of income and expenses recognised during the period					
Balance as of 30.06.2026	49 033	2 806	4 719	5 470	62 028

Date of preparation: 23.07.2026
Sofia

Prepared by: 
/ Tsvetelina Pandeva /

Executive Director: 
/ Biser Georgiev /